Your browser is no longer supported. Please, upgrade your browser.
Aerie Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.99 Insider Own2.20% Shs Outstand45.95M Perf Week19.56%
Market Cap787.09M Forward P/E- EPS next Y-1.09 Insider Trans-3.28% Shs Float45.76M Perf Month15.81%
Income-183.10M PEG- EPS next Q-0.64 Inst Own- Short Float15.33% Perf Quarter57.61%
Sales83.10M P/S9.47 EPS this Y21.30% Inst Trans-4.85% Short Ratio9.89 Perf Half Y77.82%
Book/sh1.31 P/B14.93 EPS next Y21.80% ROA-49.90% Target Price26.83 Perf Year14.99%
Cash/sh5.43 P/C3.60 EPS next 5Y- ROE-181.80% 52W Range9.01 - 20.35 Perf YTD44.78%
Dividend- P/FCF- EPS past 5Y-17.10% ROI-52.70% 52W High-3.88% Beta0.53
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin69.50% 52W Low117.09% ATR1.23
Employees380 Current Ratio3.30 Sales Q/Q8.60% Oper. Margin- RSI (14)68.12 Volatility9.45% 6.63%
OptionableYes Debt/Eq3.41 EPS Q/Q20.60% Profit Margin- Rel Volume1.36 Prev Close19.80
ShortableYes LT Debt/Eq3.41 EarningsFeb 25 AMC Payout- Avg Volume709.45K Price19.56
Recom1.90 SMA2014.85% SMA5024.33% SMA20045.74% Volume950,835 Change-1.21%
Oct-19-20Downgrade BofA Securities Neutral → Underperform $14 → $9
Sep-08-20Resumed Guggenheim Buy $20
Aug-07-20Reiterated Needham Buy $32 → $26
Jun-01-20Resumed Oppenheimer Outperform $22 → $24
May-07-20Reiterated H.C. Wainwright Buy $37 → $31
Jan-10-20Initiated BofA/Merrill Neutral $27
Jan-09-20Initiated SunTrust Buy $32
Dec-19-19Initiated Citigroup Buy $36
Nov-07-19Reiterated H.C. Wainwright Buy $55 → $41
Oct-30-19Reiterated Needham Buy $54 → $48
Aug-08-19Reiterated Needham Buy $74 → $54
Aug-08-19Reiterated Cantor Fitzgerald Overweight $85 → $62
Mar-21-19Initiated Piper Jaffray Overweight $80
Jul-13-18Reiterated Needham Buy $76 → $86
Feb-16-18Resumed H.C. Wainwright Buy $78
Jan-26-18Initiated Seaport Global Securities Buy $78
Oct-24-17Initiated Guggenheim Buy $80
Oct-16-17Reiterated Needham Buy $65 → $76
Jul-20-17Reiterated Cantor Fitzgerald Overweight $56 → $62
May-25-17Reiterated Needham Buy $58 → $65
Mar-03-21 05:33PM  
Mar-01-21 10:59AM  
Feb-28-21 04:59AM  
Feb-25-21 05:45PM  
Feb-22-21 07:30AM  
Feb-18-21 07:30AM  
Jan-11-21 06:30AM  
Dec-16-20 11:07PM  
Dec-05-20 11:31AM  
Dec-03-20 11:17PM  
Nov-25-20 10:36AM  
Nov-16-20 10:06AM  
Nov-13-20 06:50AM  
Nov-10-20 07:30AM  
Nov-07-20 01:30AM  
Nov-06-20 10:50AM  
Nov-05-20 06:25PM  
Nov-03-20 09:46AM  
Oct-29-20 12:35PM  
Oct-28-20 03:00AM  
Oct-27-20 07:30AM  
Oct-20-20 06:28AM  
Oct-15-20 09:20AM  
Oct-14-20 12:30AM  
Oct-05-20 12:01PM  
Sep-30-20 09:10AM  
Sep-29-20 06:30AM  
Sep-24-20 06:30AM  
Sep-18-20 09:00AM  
Sep-15-20 06:45AM  
Sep-09-20 07:45AM  
Sep-08-20 07:30AM  
Sep-05-20 11:31AM  
Aug-21-20 09:01AM  
Aug-10-20 10:01AM  
Aug-07-20 10:53AM  
Aug-06-20 04:01PM  
Jul-30-20 07:30AM  
Jul-29-20 12:33PM  
Jul-27-20 06:30AM  
Jul-17-20 02:06PM  
Jul-02-20 08:11AM  
Jun-15-20 06:04PM  
Jun-11-20 06:30AM  
Jun-05-20 11:31AM  
Jun-03-20 03:40AM  
May-11-20 07:15PM  
May-07-20 06:30PM  
May-06-20 05:15PM  
May-05-20 07:30AM  
Apr-29-20 07:30AM  
Apr-28-20 12:34PM  
Apr-13-20 10:01AM  
Apr-09-20 04:01PM  
Apr-07-20 07:30AM  
Apr-02-20 02:54PM  
Mar-25-20 10:18AM  
Mar-21-20 11:30AM  
Feb-27-20 07:23AM  
Feb-24-20 02:59PM  
Feb-21-20 11:30AM  
Feb-20-20 05:35PM  
Feb-18-20 06:30AM  
Feb-13-20 07:30AM  
Feb-12-20 05:13AM  
Feb-03-20 06:30AM  
Jan-21-20 06:30AM  
Jan-08-20 05:18PM  
Jan-07-20 05:26AM  
Jan-03-20 10:04AM  
Jan-02-20 08:46AM  
Dec-09-19 06:30AM  
Dec-06-19 11:31AM  
Dec-04-19 09:19AM  
Dec-03-19 06:15AM  
Dec-02-19 04:56AM  
Nov-27-19 09:45AM  
Nov-26-19 06:30AM  
Nov-22-19 08:18AM  
Nov-21-19 06:30AM  
Nov-19-19 10:58AM  
Nov-18-19 06:30AM  
Nov-12-19 07:30AM  
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kopczynski Casey C.Chief Scientific OfficerFeb 15Option Exercise0.2060,65111,888265,522Feb 17 05:40 PM
Kopczynski Casey C.Chief Scientific OfficerNov 11Sale13.0122,695295,210196,114Nov 12 05:03 PM
Kopczynski Casey C.Chief Scientific OfficerNov 10Sale13.007,30594,965218,809Nov 12 05:03 PM
GOLDBERG MURRAY ADirectorMay 18Option Exercise3.1528,00088,20036,050May 20 06:45 PM
Cagle Gerald D.DirectorMay 08Sale15.275,00076,35016,550May 12 05:25 PM